Advancing Early Cancer Detection: Precision & Equity
*Corresponding Author: Carla Montenegro, Lisbon Oncology Research Centre, Portugal, Email: c.montenegro@lisbooncology.ptReceived Date: Nov 01, 2025 / Accepted Date: Dec 01, 2025 / Published Date: Dec 01, 2025
Citation: Montenegro C (2025) Advancing Early Cancer Detection: Precision & Equity. jcd 09: 326.DOI: 10.4172/2476-2253.1000326
Copyright: © 2025 Carla Montenegro This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permitsunrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Abstract
Advances in early cancer detection are transforming patient care through innovative non-invasive and precision approaches. Liq
uid biopsy, \textit{Artificial Intelligence} (AI), and Multi-Cancer Early Detection (MCED) tests offer enhanced capabilities for early
diagnosis and monitoring. Screening for specific cancers like lung, cervical, colorectal, and prostate is evolving with advanced imag
ing, Human Papillomavirus (HPV) testing, and novel biomarkers. The integration of genomics further personalizes risk assessment
and prevention. Despite these strides, addressing persistent disparities in screening access remains vital for equitable outcomes,
underscoring a dynamic field moving towards earlier, more effective intervention.
